2026 SSC Adult Guidelines Updates: What Clinicians Need to Know-Handouts

Handouts

Pdf Summary

This document outlines an April 7, 2026 educational webinar on the forthcoming <strong>2026 Surviving Sepsis Campaign (SSC) Adult Guidelines</strong> and highlights how the update was developed and what is new versus unchanged. Session moderators and guideline co-chairs are introduced along with financial disclosures and an educational-use disclaimer.

The guideline update was produced by a <strong>69-member international panel from 23 countries</strong>, with substantial representation outside Europe/North America and meaningful experience in low- and middle-income countries. The organizational structure included topic-based subgroups (e.g., screening/early management, infection, hemodynamics, respiratory support, adjunctive therapies, and goals of care), a systematic review team, a patient and family panel to prioritize outcomes and preferences, and a usability workgroup to support dissemination.

Methodologically, the update followed standards for trustworthy clinical practice guidelines using <strong>PICO questions</strong>, systematic literature searches, evidence synthesis (including meta-analysis and risk-of-bias assessment), and <strong>GRADE</strong> to rate certainty of evidence. Recommendations were shaped through an <strong>Evidence-to-Decision (EtD) framework</strong> considering benefits/harms, values, resources, equity, acceptability, and feasibility. Draft recommendations were debated in person (March 2025) and finalized through multiple voting rounds with high participation and agreement.

Key content highlights include:
- <strong>Screening/Early management:</strong> <em>Insufficient evidence</em> to recommend <strong>novel rapid host diagnostics</strong>.
- <strong>Antibiotic management:</strong> <strong>Timing remains the same as 2021</strong>, while <strong>antibiotic selection places greater emphasis on stewardship</strong>.
- Several statements were <strong>upgraded from conditional to strong recommendations</strong>, including areas informed by newer evidence (e.g., a 2024 JAMA meta-analysis on prolonged vs intermittent β-lactam infusions).
- Added attention to <strong>therapeutic drug monitoring</strong> (balancing efficacy and toxicity) and <strong>source control</strong>.
- <strong>Hemodynamic monitoring/resuscitation</strong> evidence certainty was upgraded in parts (e.g., low→moderate; very low→low), and multiple “**In Our Practice**” statements address practical issues such as peripheral vasopressors, vasopressin/epinephrine add-on criteria, SpO₂ targets, and corticosteroid use.

The SSC website will provide <strong>new tools</strong> to support guideline implementation.

Keywords

2026 Surviving Sepsis Campaign Adult Guidelines

sepsis guideline update webinar April 2026

GRADE evidence certainty

PICO questions systematic review

Evidence-to-Decision framework EtD

international guideline panel 23 countries

sepsis screening early management rapid host diagnostics

antibiotic timing and stewardship sepsis

beta-lactam prolonged vs intermittent infusion meta-analysis 2024

hemodynamic resuscitation monitoring peripheral vasopressors

	Society of Critical Care Medicine 500 Midway Drive Mount Prospect, IL 60056 USA Phone: +1 847 827-6888 Fax: +1 847 439-7226 Email: support@sccm.org	Contact Us About SCCM Newsroom Advertising & Sponsorship DONATE	MySCCM LearnICU Patients & Families Surviving Sepsis Campaign Critical Care Societies Collaborative	GET OUR NEWSLETTER
© Society of Critical Care Medicine. All rights reserved. \| Privacy Statement \| Terms & Conditions The Society of Critical Care Medicine, SCCM, and Critical Care Congress are registered trademarks of the Society of Critical Care Medicine.